{
  "docId": "019de073-aaaa-768c-937f-f768840b87a6",
  "docSlug": "9b8664e841ca83938179aa04bf759b1d",
  "documentTitle": "BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides",
  "authorId": "brainstorm-cell-therapeutics",
  "authorName": "Brainstorm Cell Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 15,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "Mentions specific statistical models: PCA, MMRM, and mixed stepwise regression.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-aaaa-768c-937f-f768840b87a6/6",
  "deckHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6",
  "deckJsonHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6.json",
  "deckAnchorHref": "/decks/019de073-aaaa-768c-937f-f768840b87a6#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.85,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "list",
      "text": "7 CSF samples over 20 weeks - collected prior to and after each treatment; Validated assays at Thermo Fisher, Quanterix, Olink, Ray Biotech and Norgen; Biomarker Statistical Analysis Plan submitted to FDA before trial unblinding; Due to skewness in the distribution, biomarker data are log transformed for statistical analysis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61b6280c-72d8-4d22-9af0-155c97031616",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.95,
        "x": 0.03,
        "y": 0.5
      },
      "kind": "list",
      "text": "1. Principal Component Analysis - used biomarker data from the treatment period, and pre-specified biological pathways to identify groups of relevant biomarkers. 2. Individual Biomarker Trajectories - plotted using an MMRM model 3. Prediction of NurOwn Response - mixed stepwise regression model selected significant biomarkers predicting response to NurOwn.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "38ccb30b-5140-46bf-afb1-a37f630e9754",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.28,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Biomarker Analysis Methods",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "036a9223-6da4-4963-bd84-2d2a08c51dad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.03,
        "y": 0.045
      },
      "kind": "title",
      "text": "Three Main Analyses",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3d8979a-5763-4c9d-93b2-a54b3e171232",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "analytical-method",
      "slug": null,
      "matchId": "76586660-e31c-41e7-85f3-8180b9822a17",
      "evidence": "Outlines specific statistical and analytical procedures for clinical trial data.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 6,
      "beatId": "1e09c995-6c2c-4ea3-94d4-8282e303405f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 6-14 present NurOwn as a potential solution",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 3,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "bce1965c-83ec-40d6-9c4c-8bfd12826169",
      "evidence": "Slides 3 and 10 present before-after comparisons",
      "position": 0,
      "objective": "Show the effect of NurOwn treatment on biomarkers",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}